Skin Cancer Services are a core part of St John's Institute of Dermatology and make a significant contribution to our status as a world-leading centre for skin disease treatment and research.
Specialist skin cancer multidisciplinary team (SSMDT) research
Members of the SSMDT have played an active role in research relating to Dermoscopy and confocal microscopy, and are seeking to translate their work into improving diagnostic and therapeutic services for skin cancer patients at Guy's and St Thomas' Hospitals.
Research within the Melanoma team employs a truly multidisciplinary approach. It involves participation by all clinicians from the SSMDT and Melanoma team, scientists based in both the division of genetics and molecular medicine and the division of cancer studies at Kings College London, as well as external collaborators in the division of immunology at University College London. We also have a dedicated research nurse who is funded through the Experimental Cancer Medicine Centre.
Our research is focused around five key strategic areas:
- tissue bank: patients seen in the melanoma clinic are consented for any tissue surplus to diagnostic requirements to be stored in the St John's Institute of Dermatology research tissue bank
- melanoma database: we have a dedicated melanoma database which has been developed in-house. The database is a powerful research tool and is closely linked to our research tissue bank. It also enables us to provide accurate data on incidence and survival within the south east London cancer sector
- clinical trials: we have a broad portfolio of clinical trials
- translational cancer immunology/immunotherapy programme
- skin imaging programme: we are currently developing novel skin imaging techniques for the diagnosis of skin cancer including the use of Optical Coherence Tomography and Confocal Microscopy.
The Cutaneous T-Cell Lymphoma (CTCL) research
Research within the CTCL team involves participation by all clinicians from the SSMDT and CTCL team, and scientists based in within genetics and molecular medicine and cancer studies at King's College London. This allows us to deliver translational research with a view to discovering potential diagnostic and therapeutic targets that will lead to meaningful outcomes for patient care.